These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

328 related articles for article (PubMed ID: 31733455)

  • 1. Dose increase of S-Adenosyl-Methionine and escitalopram in a randomized clinical trial for major depressive disorder.
    Sakurai H; L Carpenter L; R Tyrka A; Price LH; I Papakostas G; Dording CM; Yeung AS; Cusin C; Ludington E; Bernard-Negron R; Fava M; Mischoulon D
    J Affect Disord; 2020 Feb; 262():118-125. PubMed ID: 31733455
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A double-blind, randomized, placebo-controlled clinical trial of S-adenosyl-L-methionine (SAMe) versus escitalopram in major depressive disorder.
    Mischoulon D; Price LH; Carpenter LL; Tyrka AR; Papakostas GI; Baer L; Dording CM; Clain AJ; Durham K; Walker R; Ludington E; Fava M
    J Clin Psychiatry; 2014 Apr; 75(4):370-6. PubMed ID: 24500245
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Single i.v. ketamine augmentation of newly initiated escitalopram for major depression: results from a randomized, placebo-controlled 4-week study.
    Hu YD; Xiang YT; Fang JX; Zu S; Sha S; Shi H; Ungvari GS; Correll CU; Chiu HF; Xue Y; Tian TF; Wu AS; Ma X; Wang G
    Psychol Med; 2016 Feb; 46(3):623-35. PubMed ID: 26478208
    [TBL] [Abstract][Full Text] [Related]  

  • 4. S-adenosyl methionine (SAMe) versus escitalopram and placebo in major depression RCT: efficacy and effects of histamine and carnitine as moderators of response.
    Sarris J; Papakostas GI; Vitolo O; Fava M; Mischoulon D
    J Affect Disord; 2014 Aug; 164():76-81. PubMed ID: 24856557
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Duloxetine versus escitalopram and placebo: an 8-month, double-blind trial in patients with major depressive disorder.
    Pigott TA; Prakash A; Arnold LM; Aaronson ST; Mallinckrodt CH; Wohlreich MM
    Curr Med Res Opin; 2007 Jun; 23(6):1303-18. PubMed ID: 17559729
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bioavailability of S-adenosyl methionine and impact on response in a randomized, double-blind, placebo-controlled trial in major depressive disorder.
    Mischoulon D; Alpert JE; Arning E; Bottiglieri T; Fava M; Papakostas GI
    J Clin Psychiatry; 2012 Jun; 73(6):843-8. PubMed ID: 22687580
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Do equivalent doses of escitalopram and citalopram have similar efficacy? A pooled analysis of two positive placebo-controlled studies in major depressive disorder.
    Lepola U; Wade A; Andersen HF
    Int Clin Psychopharmacol; 2004 May; 19(3):149-55. PubMed ID: 15107657
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and tolerability of escitalopram versus citalopram in major depressive disorder: a 6-week, multicenter, prospective, randomized, double-blind, active-controlled study in adult outpatients.
    Yevtushenko VY; Belous AI; Yevtushenko YG; Gusinin SE; Buzik OJ; Agibalova TV
    Clin Ther; 2007 Nov; 29(11):2319-32. PubMed ID: 18158074
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A randomized, double-blind, 24-week study of escitalopram (10 mg/day) versus citalopram (20 mg/day) in primary care patients with major depressive disorder.
    Colonna L; Andersen HF; Reines EH
    Curr Med Res Opin; 2005 Oct; 21(10):1659-68. PubMed ID: 16238906
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Improved insomnia symptoms and sleep-related next-day functioning in patients with comorbid major depressive disorder and insomnia following concomitant zolpidem extended-release 12.5 mg and escitalopram treatment: a randomized controlled trial.
    Fava M; Asnis GM; Shrivastava RK; Lydiard B; Bastani B; Sheehan DV; Roth T
    J Clin Psychiatry; 2011 Jul; 72(7):914-28. PubMed ID: 21208597
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Escitalopram for severe asthma and major depressive disorder: a randomized, double-blind, placebo-controlled proof-of-concept study.
    Brown ES; Howard C; Khan DA; Carmody TJ
    Psychosomatics; 2012; 53(1):75-80. PubMed ID: 22221724
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Duloxetine for the treatment of major depressive disorder: safety and tolerability associated with dose escalation.
    Wohlreich MM; Mallinckrodt CH; Prakash A; Watkin JG; Carter WP
    Depress Anxiety; 2007; 24(1):41-52. PubMed ID: 16845641
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Randomized, Double-Blind, Placebo-Controlled Trial of Escitalopram in Patients with Asthma and Major Depressive Disorder.
    Brown ES; Sayed N; Van Enkevort E; Kulikova A; Nakamura A; Khan DA; Ivleva EI; Sunderajan P; Bender BG; Holmes T
    J Allergy Clin Immunol Pract; 2018; 6(5):1604-1612. PubMed ID: 29409976
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effects of vortioxetine on cognitive dysfunction in patients with inadequate response to current antidepressants in major depressive disorder: A short-term, randomized, double-blind, exploratory study versus escitalopram.
    Vieta E; Sluth LB; Olsen CK
    J Affect Disord; 2018 Feb; 227():803-809. PubMed ID: 29673132
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A double-blind, randomized parallel-group, efficacy and safety study of intramuscular S-adenosyl-L-methionine 1,4-butanedisulphonate (SAMe) versus imipramine in patients with major depressive disorder.
    Pancheri P; Scapicchio P; Chiaie RD
    Int J Neuropsychopharmacol; 2002 Dec; 5(4):287-94. PubMed ID: 12466028
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ziprasidone Augmentation of Escitalopram for Major Depressive Disorder: Efficacy Results From a Randomized, Double-Blind, Placebo-Controlled Study.
    Papakostas GI; Fava M; Baer L; Swee MB; Jaeger A; Bobo WV; Shelton RC
    Am J Psychiatry; 2015 Dec; 172(12):1251-8. PubMed ID: 26085041
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A randomized controlled trial of the efficacy and safety of lisdexamfetamine dimesylate as augmentation therapy in adults with residual symptoms of major depressive disorder after treatment with escitalopram.
    Trivedi MH; Cutler AJ; Richards C; Lasser R; Geibel BB; Gao J; Sambunaris A; Patkar AA
    J Clin Psychiatry; 2013 Aug; 74(8):802-9. PubMed ID: 24021497
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The vasopressin V(1b) receptor antagonist SSR149415 in the treatment of major depressive and generalized anxiety disorders: results from 4 randomized, double-blind, placebo-controlled studies.
    Griebel G; Beeské S; Stahl SM
    J Clin Psychiatry; 2012 Nov; 73(11):1403-11. PubMed ID: 23146246
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Desvenlafaxine 50 and 100 mg/d in the treatment of major depressive disorder: an 8-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group trial and a post hoc pooled analysis of three studies.
    Tourian KA; Padmanabhan SK; Groark J; Brisard C; Farrington D
    Clin Ther; 2009 Jun; 31 Pt 1():1405-23. PubMed ID: 19698901
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Escitalopram and duloxetine in major depressive disorder: a pharmacoeconomic comparison using UK cost data.
    Wade AG; Fernández JL; François C; Hansen K; Danchenko N; Despiegel N
    Pharmacoeconomics; 2008; 26(11):969-81. PubMed ID: 18850765
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.